AstraZeneca's U.K. Vaccine Facility at Risk Due to Government Aid Cuts, FT Reports
--AstraZeneca's planned 450 million British pound investment in a vaccine-manufacturing site in Speke, Merseyside could be at risk due to potential reduction of over 20 million pounds in U.K. treasury funding for the project, the Financial Times reported, citing unnamed sources.
--The British government sought to reduce the aid it would offer to develop the Anglo-Swedish pharma giant's nasal flu vaccine facility to 40 million pounds versus a verbal offer of 65 million pounds given by the previous administration, according to the FT.
--AstraZeneca declined to comment when contacted by Dow Jones Newswires. The Treasury confirmed that it was in ongoing talks with AstraZeneca. "The chancellor receives regular updates on this planned investment in Speke, and we are in positive discussions with AstraZeneca to support its delivery," a spokesperson said.
Full story: htTps://bit.ly/3YKxQ0R
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
August 14, 2024 08:44 ET (12:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued